A 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment-resistant depression

Journal of Affective Disorders

Volumn 147, Issue 1-3, 2013, Pages 416-420

  Szymkowicz, Sarah M ^a   Finnegan, Nora ^b   Dale, Roman M ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b Lutheran Hospital Cleveland   (United States)

Author keywords

Depression; Ketamine; Repeat infusions; Treatment resistant depression

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; CHLORPROMAZINE; CLONAZEPAM; FLUOXETINE; GABAPENTIN; KETAMINE; LAMOTRIGINE; LITHIUM; LORAZEPAM; MELATONIN; NORTRIPTYLINE; PHENELZINE; PLACEBO; QUETIAPINE; SODIUM CHLORIDE; TEMAZEPAM;

ADOLESCENT; ARTICLE; CASE REPORT; CLINICAL ASSESSMENT; DISEASE SEVERITY; DRUG EFFICACY; ELECTROCONVULSIVE THERAPY; HOSPITAL DISCHARGE; HUMAN; LONG TERM CARE; LOW DRUG DOSE; MAINTENANCE THERAPY; MAJOR DEPRESSION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OBSERVATIONAL STUDY; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZATION; SUICIDAL IDEATION; SUICIDE ATTEMPT; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE;

ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KETAMINE; MALE; MIDDLE AGED;

EID: 84875366335     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2012.10.015     Document Type: Article

References (40)

1. M. aan het Rot, D.S. Charney, and S.J. Mathew Intravenous ketamine for treatment resistant major depressive disorder Primary Psychiatry 15 2008 39 47
2. M. aan het Rot, K.A. Collins, J.W. Murrough, A.M. Perez, D.L. Reich, D.S. Charney, and S.J. Mathew Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression Biological Psychiatry 67 2010 139 145
3. A.S. Arachchige Don, and X.S. Zheng Recent clinical trials of mTOR-targeted cancer therapies Reviews on Recent Clinical Trials 6 2010 24 35
4. M.T. Berlim, and G. Turecki What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials European Neuropsychopharmacology 17 2007 696 707
5. R.M. Berman, A. Cappiello, A. Anand, D.A. Oren, G.R. Heninger, D.S. Charney, and J.H. Krystal Antidepressant effects of ketamine in depressed patients Biological Psychiatry 47 2000 351 354
6. N. Diazgranados, L. Ibrahim, N.E. Brutsche, A. Newberg, P. Kronstein, S. Khalife, W.A. Kammerer, Z. Quezado, D.A. Luckenbaugh, G. Salvadore, R. Machado-Vieira, H.K. Manji, and C.A. Zarate A randomized add-on trial of an N-methyl-d-aspartate antagonist in treatment-resistant bipolar depression Archives of General Psychiatry 67 2010 793 802
7. P. Dillon, J. Copeland, and K. Jansen Patterns of use and harms associated with non-medical ketamine use Drug and Alcohol Dependence 69 2003 23 28
8. L.S.B. Garcia, C.M. Comim, S.S. Valvassori, G.Z. Reus, L.M. Barbosa, A.C. Andreazza, L. Stertz, G.R. Fries, E.C. Gavioli, F. Kapczinski, and J. Quevedo Acute administration of ketamine induces antidepressant-like effects in a forced swimming test and increases BDNF levels in the rat hippocampus Progress in Neuro-Psychopharmacology and Biological Psychiatry 32 2008 140 144
9. K. Hashimoto, A. Sawa, and M. Iyo Increased levels of glutamate in brains from patients with mood disorders Biological Psychiatry 62 2007 1310 1316
10. K. Hashimoto Emerging role of glutamate in the pathophysiology of major depressive disorder Brain Research Reviews 61 2009 105 123
11. G. Hasler, J.W. Van Der Veen, T. Tumonis, N. Meyers, J. Shen, and W.C. Drevets Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy Archives of General Psychiatry 64 2007 193 200
12. C.J. Hawley, T.M. Gale, and T. Sivakumaran Defining remission by cut off score on the MADRS: selecting the optimal value Journal of Affective Disorders 72 2002 177 184
13. S.A. Irwin, and A. Iglewicz Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care Journal of Palliative Medicine 13 2010 903 908
14. H. Koike, M. Iijima, and S. Chaki Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression Behavioral Brain Research 224 2011 107 111
15. J.H. Krystal, G. Sanacora, H. Blumberg, A. Anand, D.S. Charney, G. Marek, C.N. Epperson, A. Goddard, and G.F. Mason Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments Molecular Psychiatry 7 Suppl. 1 2002 S71 S80
16. A. Kudoh, Y. Takahira, H. Katagai, and T. Takazawa Small-dose ketamine improves the postoperative state of depressed patients Anesthesia and Analgesia 95 2002 114 118
17. N. Li, B. Lee, R. Liu, M. Banasr, J.M. Dwyer, M. Iwata, X. Li, G. Aghajanian, and R.S. Duman mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists Science 329 2010 959 964
18. N. Li, R. Liu, J.M. Dwyer, M. Banasr, B. Lee, H. Son, X. Li, G. Aghajanian, and R.S. Duman Glutamate N-methyl-d-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure Biological Psychiatry 69 2011 754 761
19. M. Liebrenz, A. Borgeat, R. Lesinger, and R. Stohler Intravenous ketamine therapy in a patient with a treatment-resistant major depression Swiss Medical Weekly 137 2007 234 246
20. M. Liebrenz, R. Stohler, and A. Borgeat Repeated intravenous ketamine therapy in a patient with a treatment resistant major depression World Journal of Biological Psychiatry 10 2009 640 643
21. S. Maeng, and C.A. Zarate The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects Current Psychiatry Reports 9 2007 467 474
22. S. Maeng, C.A. Zarate, J. Du, R.J. Schloesser, J. McCammon, G. Chen, and H.K. Manji Cellular mechanisms underlying the antidepressant effects of ketamine: role of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors Biological Psychiatry 63 2008 349 352
23. S.J. Mathew, J.W. Murrough, M. aan het Rot, K.A. Collins, D.L. Reich, and D.S. Charney Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial International Journal of Neuropsychopharmacology 13 2010 71 82
24. M.M. Messer, and I.V. Haller Maintenance ketamine treatment produces long-term recovery from depression Primary Psychiatry 17 2010 48 50
25. M.M. Messer, I.V. Haller, P. Larson, J. Pattison-Crisostomo, and C.H. Gessert The use of a series of ketamine infusions in two patients with treatment-resistant depression Journal of Neuropsychiatry and Clinical Neurosciences 22 2010 442 444
26. S.A. Montgomery, and M. Asberg A new depression scale designed to be sensitive to change British Journal of Psychiatry 134 1979 382 389
27. C.J. Murray, and A.D. Lopez Evidence-based health policy-lessons from the global burden of disease study Science 27 1996 740 743
28. L.E. Phelps, N. Brutsche, J.R. Moral, D.A. Luckenbaugh, H.K. Manji, and C.A. Zarate Family history of alcohol dependence an initial antidepressant response to an N-methyl-d-aspartate antagonist Biological Psychiatry 65 2009 181 184
29. R.B. Price, D.C. Shungu, X. Mao, P. Nestadt, C. Kelly, K.A. Collins, J.W. Murrough, D.S. Charney, and S.J. Mathew Amino acid neurotransmitters assessed by proton magnetic resonance spectroscopy: relationship to treatment resistance in major depressive disorder Biological psychiatry 65 2009 792 800
30. G. Salvadore, B.R. Cornwell, V. Colon-Rosario, R. Coppola, C. Grillon, C.A. Zarate, and H.K. Manji Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine Biological Psychiatry 65 2009 289 295
31. G. Sanacora, R. Gueorguieva, C.N. Epperson, Y.T. Wu, M. Appel, D.L. Rothman, J.H. Krystal, and G.F. Mason Subtype-specific alterations of gamma-animobutyric acid and glutamate in patients with major depression Archives of General Psychiatry 61 2004 705 713
32. E. Scarr, G. Pavey, S. Sundram, A. MacKinnon, and B. Dean Decreased hippocampal NMDA, but not kainite or AMPA receptors in bipolar depression Bipolar Disorders 5 2003 257 264
33. D. Sheehan, Y. Lecrubier, L. Harnett-Sheehan, P. Amorim, J. Janavs, E. Weiller, T. Hergueta, R. Baker, and G. Dunbar The Mini International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview Journal of Clinical Psychiatry 59 1998 22 33
34. L. Stefanczyk-Sapieha, D. Oneschuk, and M. Demas Intravenous ketamine burst for refractory depression in a patient with advanced cancer Journal of Palliative Medicine 11 2008 1268 1271
35. M.E. Thase, B.R. Haight, N. Richard, C.B. Rockett, M. Mitton, J.G. Modell, S. Vanmeter, A.E. Harriett, and Y. Yang Remission rates following antidepressant therapy with buproprion or selective serotonin reuptake inhibitors: a meta-analysis of original date from 7 randomized controlled trials Journal of Clinical Psychiatry 66 2005 974 981
36. A. Yildiz-Yesiloglu, and D.P. Ankerst Neurochemical alterations of the br4ain in bipolar disorder and their implications for pathophysiology: a systematic review of the in vivo proton magnetic resonance spectroscopy findings Progress in Neuro-Psychopharmacology and Biological Psychiatry 30 2006 969 995
37. A. Yilmaz, D. Schulz, A. Aksoy, and R. Canbeyli Prolonged effect of an anesthetic dose of ketamine on behavioral despair Pharmacology Biochemistry and Behavior 71 2002 341 344
38. C.A. Zarate, J. Quiroz, J. Payne, and H.K. Manji Modulators of the glutamatergic system: implications for the development of improved therapeutics in mood disorders Psychopharmacology Bulletin 36 2002 35 83
39. C.A. Zarate, J.B. Singh, P.H. Carlson, N.E. Brutsche, R. Ameli, D.A. Luckenbaugh, D.S. Charney, and H.K. Manji A randomized trial of an N-methly-d-aspartate antagonist in treatment-resistant major depression Archives of General Psychiatry 63 2006 856 864
40. C. Zarate, R. Machado-Vieira, I. Henter, L. Ibrahim, N. Diazgranados, and G. Salvadore Glutamatergic modulators: the future of treating mood disorders? Harvard Review of Psychiatry 18 2010 293 303